Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Resectable Hepatocellular Carcinoma With Intermediate or High Recurrence Risk”

2 trials

Showing 2 of 2 results

Testing effectiveness (Phase 2)Not Yet RecruitingNCT07682272
What this trial is testing

A Trial of SHR-8068 Combined With Adebrelimab and Apatinib in Perioperative Treatment of Resectable Hepatocellular Carcinoma

Who this might be right for
Resectable Hepatocellular Carcinoma With Intermediate or High Recurrence Risk
Suzhou Suncadia Biopharmaceuticals Co., Ltd. 120
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07487662
What this trial is testing

TACE or Ablation Combined With Sintilimab and Ipilimumab N01 as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With Intermediate-High Recurrence Risk

Who this might be right for
Hepato Cellular Carcinoma (HCC)
Sun Yat-sen University 105

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation